Skip to main content

Table 1 Clinicopathological characteristics in relation to MMP9, MMP2, Type IV collagen and Macrophages immunoreactivity

From: Co-evolution of cancer microenvironment reveals distinctive patterns of gastric cancer invasion: laboratory evidence and clinical significance

Variables N MMP9 Positive
(%)
P* MMP2 positive
(%)
P* Type IV collagen Positive
(%)
P* Macrophages counts
(M ± SD)
P**
Age (yr)
   ≤ 58 18 13 (72.2) NS 9 (50.0) NS 12 (66.7) 0.042 19.9 ± 10.6 NS
   > 58 19 17 (89.5)   11 (57.9)   18 (94.7)   19.4 ± 7.3  
Recurrence
   No 13 10 (76.9) NS 4 (30.8) 0.047 # 10 (76.9) NS 17.3 ± 7.9 NS
   Yes 24 20 (83.3)   16 (66.7)   20 (83.3)   21.0 ± 9.4  
Serosa invasion
   No 8 7 (87.5) NS 4 (50) NS 7 (87.5) NS 12.7 ± 9.2 0.011
   Yes 29 23 (79.3)   16 (55.2)   23 (79.3)   21.6 ± 8.0  
Lymph node metastasis
   No 10 8 (80.0) NS 3 (30.0) NS 10 (100) NS 16.3 ± 8.3 NS
   Yes 27 22 (81.5)   17 (63.0)   20 (74.1)   20.9 ± 9.0  
Distant Metastasis
   M0 29 23 (79.3) NS 13 (44.8) 0.048 25 (86.2) NS 18.9 ± 8.3 0.09
   M1 8 7 (87.5)   7 (87.5)   5 (62.5)   22.6 ± 11.0  
TNM Stage          
   Early 11 9 (81.8) NS 3 (27.3) NS 10 (90.9) NS 12.8 ± 7.1 0.001
   Advanced 26 21 (80.8)   17 (65.4)   20 (76.9)   22.6 ± 8.1  
  1. * Fisher's exact test (two-tailed), bold face representing significant data (P < 0.05), NS: No statistically significant.
  2. ** t-test (two-tailed), bold face representing significant data (P < 0.05), NS: No statistically significant.
  3. # The differences of MMP2 expression among different recurrence area (distant recurrence, local recurrence and ovarian recurrence) are statistically significant, too (P = 0.024).